- Home
- PULM vs SCNX Comparison
PULM vs SCNX Comparison
Compare PULM & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- SCNX
- Stock Information
- Founded
- PULM 2003
- SCNX 2010
- Country
- PULM United States
- SCNX United States
- Employees
- PULM N/A
- SCNX N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- SCNX Other Pharmaceuticals
- Sector
- PULM Health Care
- SCNX Health Care
- Exchange
- PULM Nasdaq
- SCNX Nasdaq
- Market Cap
- PULM 18.3M
- SCNX 21.2M
- IPO Year
- PULM N/A
- SCNX 2020
- Fundamental
- Price
- PULM $4.89
- SCNX $0.86
- Analyst Decision
- PULM
- SCNX
- Analyst Count
- PULM 0
- SCNX 0
- Target Price
- PULM N/A
- SCNX N/A
- AVG Volume (30 Days)
- PULM 9.6K
- SCNX 475.0K
- Earning Date
- PULM 11-07-2025
- SCNX 11-05-2025
- Dividend Yield
- PULM N/A
- SCNX N/A
- EPS Growth
- PULM N/A
- SCNX N/A
- EPS
- PULM N/A
- SCNX N/A
- Revenue
- PULM $369,000.00
- SCNX $128,202.00
- Revenue This Year
- PULM N/A
- SCNX N/A
- Revenue Next Year
- PULM $134.88
- SCNX N/A
- P/E Ratio
- PULM N/A
- SCNX N/A
- Revenue Growth
- PULM N/A
- SCNX N/A
- 52 Week Low
- PULM $1.96
- SCNX $0.69
- 52 Week High
- PULM $10.40
- SCNX $9.55
- Technical
- Relative Strength Index (RSI)
- PULM 45.65
- SCNX 31.19
- Support Level
- PULM $4.70
- SCNX $0.86
- Resistance Level
- PULM $5.19
- SCNX $1.16
- Average True Range (ATR)
- PULM 0.15
- SCNX 0.09
- MACD
- PULM 0.07
- SCNX 0.02
- Stochastic Oscillator
- PULM 44.44
- SCNX 10.51
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.